BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Extra | Oct 22, 2019
Politics & Policy

Trump re-launches science advisory committee

Ending a two-year hiatus in its operations, President Donald Trump has revived the President’s Council of Advisors on Science and Technology (PCAST). The initial slate of members includes one person with life sciences expertise, Sharon...
BioCentury | Mar 10, 2017
Finance

Second wind

Gimv and Sofinnova Partners are backing Breath Therapeutics Holding B.V. with one of the largest European series A rounds in the past 10 years because they believe the company has solved the issues that prevented...
BioCentury | Feb 25, 2017
Product Development

mRNA test kitchens

Enough of the early challenges in mRNA have been solved to convince several pharmas and biotechs to enter into partnerships to create products capitalizing on the technology’s advantages over existing modalities. The deals span applications...
BC Innovations | Dec 22, 2016
Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BioCentury | Nov 2, 2015
Finance

Expansion capital

GHO Capital expects the common thread among its private equity deals will be healthcare companies that want to grow a nascent revenue stream by geographic expansion in Europe. The firm plans to make eight or...
BC Week In Review | Sep 15, 2014
Clinical News

Moxifloxacin: Phase III data

Data from 1,931 TB patients in the per protocol (PP) population of the double-blind, international Phase III REMoxTB trial showed that both moxifloxacin-containing TB regimens missed the primary endpoint of non-inferiority to standard of care...
Items per page:
1 - 10 of 1718
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BC Extra | Oct 22, 2019
Politics & Policy

Trump re-launches science advisory committee

Ending a two-year hiatus in its operations, President Donald Trump has revived the President’s Council of Advisors on Science and Technology (PCAST). The initial slate of members includes one person with life sciences expertise, Sharon...
BioCentury | Mar 10, 2017
Finance

Second wind

Gimv and Sofinnova Partners are backing Breath Therapeutics Holding B.V. with one of the largest European series A rounds in the past 10 years because they believe the company has solved the issues that prevented...
BioCentury | Feb 25, 2017
Product Development

mRNA test kitchens

Enough of the early challenges in mRNA have been solved to convince several pharmas and biotechs to enter into partnerships to create products capitalizing on the technology’s advantages over existing modalities. The deals span applications...
BC Innovations | Dec 22, 2016
Product R&D

Fever pace for Zika

In less than two years since emerging as a global threat, the Zika virus has prompted an unprecedented acceleration of public and private translational research that has already put three vaccine candidates in the clinic....
BioCentury | Aug 1, 2016
Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BioCentury | Nov 2, 2015
Finance

Expansion capital

GHO Capital expects the common thread among its private equity deals will be healthcare companies that want to grow a nascent revenue stream by geographic expansion in Europe. The firm plans to make eight or...
BC Week In Review | Sep 15, 2014
Clinical News

Moxifloxacin: Phase III data

Data from 1,931 TB patients in the per protocol (PP) population of the double-blind, international Phase III REMoxTB trial showed that both moxifloxacin-containing TB regimens missed the primary endpoint of non-inferiority to standard of care...
Items per page:
1 - 10 of 1718